Sandbox Rim: Difference between revisions
Rim Halaby (talk | contribs) |
Rim Halaby (talk | contribs) |
||
Line 75: | Line 75: | ||
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | E01 | | E02 | | E03 |E01=<div style="float: left; text-align: left; width: 25em; padding:1em;"> | {{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | E01 | | E02 | | E03 |E01=<div style="float: left; text-align: left; width: 25em; padding:1em;"> | ||
'''Administer ONE of the following antiplatelet agents (before or at the time of PCI):''' <br> | '''Administer ONE of the following antiplatelet agents (before or at the time of PCI):''' <br> | ||
❑ [[P2Y12|<span style="color:white;">P2Y12</span>]] receptor inhibitors <br> | ❑ Loading dose of [[P2Y12|<span style="color:white;">P2Y12</span>]] receptor inhibitors <br> | ||
:❑ [[Clopidogrel|<span style="color:white;">Clopidogrel</span>]] 600 mg | :❑ [[Clopidogrel|<span style="color:white;">Clopidogrel</span>]] 600 mg | ||
:❑ [[Ticagrelor|<span style="color:white;">Ticagrelor</span>]] 180 mg | :❑ [[Ticagrelor|<span style="color:white;">Ticagrelor</span>]] 180 mg | ||
Line 105: | Line 105: | ||
::❑ Additional bolus of 0.3 mg/kg if needed | ::❑ Additional bolus of 0.3 mg/kg if needed | ||
::❑ Decrease infusion to 1 mg/kg/h when [[creatinine|<span style="color:white;">creatinine</span>]] clearance <30 mL/min | ::❑ Decrease infusion to 1 mg/kg/h when [[creatinine|<span style="color:white;">creatinine</span>]] clearance <30 mL/min | ||
</div>|E02=<div style="float: left; text-align: left; width: 20em; padding:1em;"> '''Administer ONE of the following antiplatelet agents | </div>|E02=<div style="float: left; text-align: left; width: 20em; padding:1em;"> '''Administer ONE of the following antiplatelet agents (before OR at the time of PCI)'''<br> | ||
'''Before [[PCI|<span style="color:white;">PCI </span>]]'''<br> | '''Before [[PCI|<span style="color:white;">PCI </span>]]'''<br> | ||
❑ [[P2Y12|<span style="color:white;">P2Y12 </span>]] receptor inhibitors <br> | ❑ Loading dose of [[P2Y12|<span style="color:white;">P2Y12 </span>]] receptor inhibitors <br> | ||
:❑ [[Clopidogrel|<span style="color:white;">Clopidogrel </span>]] (600 mg) (I-B), '''''OR'''''<br> | :❑ [[Clopidogrel|<span style="color:white;">Clopidogrel </span>]] (600 mg) (I-B), '''''OR'''''<br> | ||
:❑ [[Ticagrelor|<span style="color:white;">Ticagrelor </span>]](180 mg) (I-B)<br> | :❑ [[Ticagrelor|<span style="color:white;">Ticagrelor </span>]](180 mg) (I-B)<br> | ||
Line 120: | Line 120: | ||
<br>'''''OR'''''<br><br> | <br>'''''OR'''''<br><br> | ||
'''At the time of [[PCI|<span style="color:white;">PCI </span>]]'''<br> | '''At the time of [[PCI|<span style="color:white;">PCI </span>]]'''<br> | ||
❑ [[P2Y12|<span style="color:white;">P2Y12 </span>]] receptor inhibitors <br> | ❑ Loading dose of [[P2Y12|<span style="color:white;">P2Y12 </span>]] receptor inhibitors <br> | ||
:❑ [[Clopidogrel|<span style="color:white;">Clopidogrel </span>]] (600 mg) (I-A), '''''OR'''''<br> | :❑ [[Clopidogrel|<span style="color:white;">Clopidogrel </span>]] (600 mg) (I-A), '''''OR'''''<br> | ||
:❑ [[Ticagrelor|<span style="color:white;">Ticagrelor </span>]] (180 mg) (I-B), '''''OR''''' <br> | :❑ [[Ticagrelor|<span style="color:white;">Ticagrelor </span>]] (180 mg) (I-B), '''''OR''''' <br> |
Revision as of 02:22, 7 April 2015
FIRE: Focused Initial Rapid Evaluation
A Focused Initial Rapid Evaluation (FIRE) should be performed to identify patients in need of immediate intervention.
Boxes in the red color signify that an urgent management is needed.
Identify cardinal findings of unstable angina/ NSTEMI : ❑ Chest pain or chest discomfort
❑ Characteristic ECG changes consistent with unstable angina/ NSTEMI
| |||||||||||||||||||||||
Rule out life threatening alternative diagnoses: ❑ Aortic dissection (suggestive findings: vomiting, subcutaneous emphysema) | |||||||||||||||||||||||
Begin initial treatment: ❑ Administer aspirin (I-A)
❑ Administer 2-4 L/min oxygen via nasal cannula when saturation <90%
❑ Administer beta-blockers (unless contraindicated) and titrate to the heart rate and blood pressure
❑ Administer sublingual nitroglycerin 0.4 mg every 5 minutes for a total of 3 doses
❑ Administer 80 mg atorvastatin | |||||||||||||||||||||||
Does the patient have any of the following indications that require immediate angiography and revascularization ?
❑ Hemodynamic instability or cardiogenic shock | |||||||||||||||||||||||
YES | NO | ||||||||||||||||||||||
Does the patient have negative ECG findings AND negative biomarkers? | |||||||||||||||||||||||
Yes | No | ||||||||||||||||||||||
Repeat ECG and biomarkers within next 6 hours and 12 hours | |||||||||||||||||||||||
ECG and biomarkers are both negative | At least one (ECG or biomarkers) is positive | ||||||||||||||||||||||
Calculate the risk of future adverse clinical outcomes: ❑ Thrombolysis in Myocardial Infarction (TIMI) risk score, OR ❑ GRACE score | |||||||||||||||||||||||
Proceed to angiography | Intermediate or high risk Initial invasive strategy | Low risk Initial conservative strategy | |||||||||||||||||||||
Administer ONE of the following antiplatelet agents (before or at the time of PCI):
Prasugrel is contraindicated in case of prior history of strokes or TIAs, active pathological bleeding, age ≥75 years, when urgent coronary artery bypass graft surgery (CABG) is likely, body weight <60 kg, propensity to bleed, concomitant use of medications that increase the risk of bleeding
Administer ONE of the following anticoagulant therapy:
| Administer ONE of the following antiplatelet agents (before OR at the time of PCI) Before PCI
OR
OR
| Administer ONE of the following antiplatelet agents: ❑ Clopidogrel (I-B)
❑ Ticagrelor (I-B)
| |||||||||||||||||||||
❑ Perform an angiography | Continue with the complete diagnostic approach below | ||||||||||||||||||||||